Oxford, UK; 04 October 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, announces that Charles Swingland is recovering from a recent period of ill health which may take a number of weeks. In light of this, the Board has appointed Dr Annalisa Jenkins MBBS FRCP, Independent Non-Executive Director, as Acting Non-Executive Chair of the Board, effective immediately.
Sensyne Health plc (LSE: SENS) the British clinical AI technology company, today welcomes EY Global Services Limited’s announcement on the intended expansion of its current Health Outcomes Assessment platform by collaborating with Guardtime and Sensyne Health.
Sensyne Health plc (LSE:SENS), the British Clinical AI technology company, today announces that it has entered into a new strategic partnership with Evotec SE, a global drug discovery and development company, with the University of Oxford, Oxford University Innovation Ltd and Oxford Sciences Innovationaimed at accelerating the translation of research in the fields of clinical artificial intelligence and digital health at Oxford into breakthrough digital therapeutics, clinical AI algorithms and to accelerate data-driven drug discovery and development.